Lupin has acquired VISUfarma, a European specialty pharmaceutical company, to strengthen its global ophthalmology business. The acquisition provides Lupin with a broad portfolio of innovative eye health products and expands its European footprint. VISUfarma’s operations offer market expansion opportunities and diversification across major European countries. The transaction, valued at €190 million, is expected to close by the end of 2025.
Strategic Acquisition of VISUfarma
Lupin has finalized an agreement to acquire VISUfarma, a European specialty pharmaceutical company. This acquisition, announced on September 29, 2025, aims to bolster Lupin’s global specialty franchise in ophthalmology and expand its presence in the European market. VISUfarma brings a diverse portfolio of innovative eye health products and a well-established commercial infrastructure.
Deal Rationale and Benefits
The acquisition of VISUfarma aligns with Lupin’s strategic goals to enhance its specialty business and branded portfolio. VISUfarma’s established European operations provide Lupin with market expansion opportunities and diversification across key countries, including Italy, the UK, Spain, Germany, and France. Additionally, VISUfarma’s portfolio of over 60 branded ophthalmology products presents growth opportunities in the specialty segment.
VISUfarma’s Key Highlights
VISUfarma is focused on ophthalmology, offering preservative-free branded products. Key facts about VISUfarma include:
-
95% of revenues from EU4+UK with a commercial presence in over 20 countries.
-
A portfolio of over 60 branded specialty products.
-
Estimated revenue of approximately €54 million in CY25E.
Financial Terms and Outlook
Lupin will acquire 100% of VISUfarma at an enterprise value of €190 million, funded through existing cash reserves. The transaction is expected to be completed by the end of 2025, subject to customary closing conditions, and is projected to be accretive to Lupin’s growth and margin profile.
VISUfarma Product Portfolio
VISUfarma offers a comprehensive range of eye care products across various segments, including treatments for dry eye, glaucoma, and retinal health.
Source: BSE
